PharmaMar (MSE:PHM) today announced the five studies that will be presented at the World Lung Cancer Congress 2023 organized by the IASLC on its compound Zepzelca (lurbinectedin).

Among the most notable studies that will be made public are 'Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial'. Patients with recurrent platinum-sensitive small cell lung cancer (SCLC) who received a new dose of platinum immediately after lurbinectedin + doxorubicin showed improved survival compared to those who received it after topotecan/CAV, suggesting that Administration of lurbinectedin as a second line to patients with relapsed platinum-sensitive SCLC does not affect the efficacy of the subsequent platinum redose, and could prolong the platinum-free interval and improve patient survival.

'Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients'. These results suggest that lurbinectedin can effectively prolong the platinum-free interval while maintaining the ability to continue platinum-based therapy, leading to improved outcomes.

As part of the conclusion of the last two studies, Dr. Ali Zeaiter, Vice President and Director of Clinical Development at PharmaMar comments: 'the effect of the reintroduction of platinum after the administration of lurbinectedin as monotherapy or in combination with doxorubicin is similar to that described previously with platinum reintroduction as second-line treatment in platinum-sensitive patients (Baize et al., 2020).This supports lurbinectedin as an alternative second-line treatment option to platinum reintroduction for patients with relapsed platinum-sensitive SCLC. platinum'

'Effectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-world Study'. The safety and efficacy results of lurbinectedin in relapsed real-world SCLC were generally consistent with those observed in the Phase II trial. Additionally, the rates of neutropenia, thrombocytopenia, anemia, and febrile neutropenia tended to be lower than those observed in the clinical trial.

'Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis.' The study continues to enroll a broader population of SCLC patients than the Phase II clinical trial that supported FDA approval. The real-world safety profile of lurbinectedin in this analysis was generally consistent with that reported in the pooled trial, with no new safety signals. Prophylactic use of G-CSF likely contributed to the low rates of neutropenia reported.

Contact:

Tel: +34 91 846 6000

Fax: 91 846 6001

Email: pharmamar@pharmamar.com

(C) 2023 Electronic News Publishing, source ENP Newswire